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Abstract
Background: Genetics research is an avenue towards understanding essential tremor (ET). Advances have been made in genetic linkage and association: there are
three reported ET susceptibility loci, and mixed but growing data on risk associations. However, causal mutations have not been forthcoming. This disappointing
lack of progress has opened productive discussions on challenges in ET and specifically ET genetics research, including fundamental assumptions in the field.
Methods: This article reviews the ET genetics literature, results to date, the open questions in ET genetics and the current challenges in addressing them.
Results: Several inherent ET features complicate genetic linkage and association studies: high potential phenocopy rates, inaccurate tremor self-reporting, and ET
misdiagnoses are examples. Increasing use of direct examination data for subjects, family members, and controls is one current response. Smaller moves towards
expanding ET phenotype research concepts into non-tremor features, clinically disputed ET subsets, and testing phenotype features instead of clinical diagnosis
against genetic data are gradually occurring. The field has already moved to considering complex trait mechanisms requiring detection of combinations of rare
genetic variants. Hypotheses may move further to consider novel mechanisms of inheritance, such as epigenetics.
Discussion: It is an exciting time in ET genetics as investigators start moving past assumptions underlying both phenotype and genetics experimental
contributions, overcoming challenges to collaboration, and engaging the ET community. Multicenter collaborative efforts comprising rich longitudinal prospective
phenotype data and neuropathologic analysis combined with the latest in genetics experimental design and technology will be the next wave in the field.
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Introduction
Essential tremor (ET) is a progressive and often disabling disorder:1–4
severe kinetic tremor can destroy abilities such as eating, drinking, and
handwriting. Even mild tremor may affect work skills and can be socially
devastating. ET is highly prevalent, estimated at 5% for age 65 years and
over.5–8 Treatment is at the level of symptom suppression, not disease
modification, and is variably effective at best.9 Despite all these moti-
vations, research on ET is relatively undeveloped. As the basic under-
lying mechanisms of ET are unknown, with controversies remaining
even in which area(s) of the brain are involved, the ability to validate
model systems is limited, and intelligently developing targeted therapeu-
tics is extremely difficult.
One approach many talented groups have turned to in the hopes of
breaking open the field is genetics. Recognition of frequently positive
tremor family history in ET dates back to its earliest definitions, with
general credit in the Western literature going to Most in 1836.10,11
Detailed ET pedigrees appear in the literature of the 1880s.12 Despite
progress in ET genetics, causal mutations have not been forthcoming.
This disappointing lack of progress has opened productive discussions
on challenges in ET and specifically ET genetics research, including
fundamental assumptions in the field.13–15 This article reviews the
basic open questions in ET genetics and key challenges in addressing
them.
Is ET a genetic disorder?
Twin studies support a large role for genes over environment in
ET.16,17 In one study, pairwise concordance in monozygotic twins
(0.60) was about double that in dizygotic twins (0.27).17 Another
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study16 noted a significant shift in concordance rates depending on the
use of Tremor Investigation Group (TRIG)-defined possible, probable,
or definite ET cases (see Deuschl et al18): including only probable and
definite cases, the concordance rates were 0.93 monozygotic twins and
0.29 dizygotic, putting the heritability for potential development of ET
at up to 99% using conservative prevalence estimates in an aged
population.
ET subjects generally self-report a positive tremor family history
over 60% of the time, but study results range widely, from 17% to
100%.10,12,19–24 Methodology is one factor. Only a fraction of ET
subjects seek medical attention; therefore, studies using clinic-based
versus community-based approaches may obtain different estimates of
positive ET family history due to selection biases.22 An ET subject with
affected family members may be more likely to seek medical attention
having observed potential treatment plans, or less likely if multiple
family members have been told treatment is ineffective or unim-
portant. In specific communities where cases can be directly
ascertained and there are detailed inheritance records, ET appears
strongly familial. For example, a study of a Swedish parish traced all
but 2 of 210 ET cases back to four ancestral couples, with an
autosomal dominant inheritance pattern.25 In addition, using direct
contact with family members rather than proband recall of family
history can greatly change results. Busenbark et al26 used a series of
escalating data steps (proband recall at a clinic visit, mail and phone
contact with probands, mail contact with first-degree relatives) to
increase an initial 68% positive family history rate to 96% in 253 US
ET cases. The true rate of familial ET remains unclear.22,27–29
Progress and issues to date:
genetic linkage and association studies
Approaching ET as a genetic disorder, work to date has created
consensus that ET likely represents a family of disorders. As discussed
in the next section, the concept of ET as genetically heterogeneous has
shifted to a complex genetics structure, assuming many genetic
changes come together to trigger disease pathology, although rare
Mendelian monogenic forms of ET may also exist. This section
reviews ET genetic linkage and association studies to date, which have
largely operated under a more basic framework, wherein a few
Mendelian monogenetic changes create a family of similar phenotypes.
We have seen some progress towards identifying causal mutations or
genetic risk factors for ET. Inherent features of ET as currently defined
directly impact progress in genetics studies.
Genetic linkage
Genetic linkage experiments are based on the idea that stretches of
chromosomes tend to be inherited together. Alleles (groups of genetic
markers) or loci (areas of DNA containing many genes) that are
‘‘linked’’ tend to stay together across meiosis because they are on the
same chromosome, and are close enough together that chromosomal
recombination during meiosis is unlikely. The farther apart alleles are,
the more likely that DNA crossovers during meiosis will separate the
alleles over time. Linkage experiments for ET hypothesize that a locus
observed in ET family members and not unaffected family members is
linked to an as-yet unidentified causal genetic change.
The logarithm base 10 of odds (LOD) score30 is a statistical test for
linkage analysis, which compares the likelihood of results if two loci are
linked to the likelihood of observing the data if two loci are not linked.
A LOD score greater than 3.0, i.e., 1,000 to 1 odds of the result
observed if the loci are linked, is by convention evidence for linkage.
LOD scores may be added up across multiple families to achieve a
final score. Another measure of genetic linkage is recombination
frequency (h). This is the frequency at which DNA crossover takes
place between two genetic areas during meiosis. It can therefore be
thought of as a measure of distance: the farther away two alleles are,
the more likely crossover events will occur and separate them over
time. A centimorgan (cM) is a genetic distance unit of 1%
recombination frequency; this is a useful estimate of real distance. As
distances increase, double crossovers become more possible, negating
the ability to detect recombination and causing a systematic under-
estimation of genetic distance; one critique of current ET loci is that
some reports put them in this potential size range.
There are three distinct reported susceptibility loci linked to ET
under autosomal dominant models (Online Mendelian Inheritance in
Man, www.omim.org): ETM1 on chromosome 3q13 (OMIM 190300),
identified with a genome-wide scan of 16 Icelandic families using
TRIG-defined definite (classic) ET as affected,31 and confirmed in four
unrelated Tajik families;32 ETM2 on 2p24 (OMIM 602134), linked in
an American (Czech descent) family;33–35 and a chromosome 6p23
region linked in two North American families with ET plus dystonia
but not families with classic ET alone (OMIM 611456).36
Only ETM1 has been independently confirmed.32 The original
Icelandic study, assuming an autosomal dominant model, reported a
parametric analysis LOD score of 3.71, or non-parametric Z score of
4.70, p,6.461026.31 Of note, the single pedigree LOD scores were
1.29 and below. The Tajik linkage study yielded a maximum pairwise
LOD score of 2.46 and maximum combined multipoint LOD score of
3.35; the authors argued for narrowing the locus from the original
(large) 10 cM range to 2 cM.32 An initial ETM2 follow-up DNA
sequencing study of Korean individuals reported sequence variants
within ETM2 found in 23 classic ET but not seven ‘‘non-classic’’ ET
or 30 controls.37 A subsequent association study of three polymorphic
markers within ETM2 in a Czech cohort was negative,38 as was a
case–control study of microsatellite markers across ETM2 in a Latvian
cohort.39 The only published ETM3 follow-up confirmation attempts
are locus exclusions in some ET families.36,40,41 This may reflect the
low parametric LOD scores from the two ETM3 pedigrees, and the
observation of multiple instances of non-penetrance in the haplotype
analysis.36 It may also reflect an ET–dystonia connection rather than
genetic heterogeneity in ‘‘classic’’ ET (see below). More ET loci exist
but await identification, as ETM1 and ETM2 have been excluded in
other genetically informative ET families.32,36,41–45 Thus, ET is a
genetically heterogeneous disorder: multiple genetic loci contribute to
similar clinical phenotypes.
Testa CM Essential Tremor Genetics Research Challenges
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services2
Genetic risks: association studies
Genetic associations provide correlative data, key starting points for
determining causal links between genetic changes and disease,
particularly in entities like ET with limited mechanistic information.
Associations of genetic variants with ET may provide connections to or
further separation from other disorders. Results on associations
between genetic variants and ET risk have been mixed (Table 1),
but they add to genetic linkage data suggesting mechanistic
heterogeneity within clinically defined ET.
A genome-wide association study (GWAS) in ET observed
association with single nucleotide polymorphisms (SNPs) in the
leucine-rich repeat- and Ig domain-containing Nogo receptor-inter-
acting protein 1 gene (LINGO1) on chromosome 15q (OMIM 609791),
outside reported ET-associated loci. The study used an Icelandic
cohort with 452 ET and 14,394 controls, then confirmed one SNP
(rs9652490) in Icelandic, US, and European ET cohorts.46 Reported
odds ratio for rs9652490 was 1.54 with a population attributable risk of
approximately 20%. The LINGO1 result has been replicated in
multiple independent samples,14,47 including European,48 North
American,49–51 Latvian,52 and Asian53 cohorts. At least one study
used only definite ET cases.48 In one study, restricting cases to
probable or definite, not possible ET, or restricting analysis to early ET
onset (age,40) strengthened the association observation.51 Multiple
LINGO1 SNPs have been proposed over the range of studies, with the
most consistent data behind rs9652490. Collectively, association
studies suggest that the LINGO1 SNP rs9652490 confers modest
increased risk for ET, with odds ratios in the range of 1.2–1.7 across
multiple studies and populations (Table 1).
Some LINGO1 studies did not replicate an association with ET, or
observed mixed results. Neither SNP from the original GWAS was
associated with risk of ET in Chinese Han,54 Spanish,55 or French
Canadian56 cohorts. A separate Chinese study found no significant
association of rs9652490 with ET;57 however, a meta-analysis
combining the initial data with published53 and unpublished data
from another cohort suggested increased ET risk with the rs9652490 G
allele in a logistic regression analysis, under a possible recessive model
for LINGO1 ET inheritance.57
The overall results in LINGO1 could be due to population-specific
differences,14 statistical issues such as multiple testing and sample sizes,
or issues in ET genetics as discussed below. Alleles (DNA sequences)
can be combined into haplotypes. Linkage disequilibrium, meaning a
non-random association between alleles at multiple loci, is the
observation of allelic combinations more (or less) often than expected
in a population, compared with haplotypes formed randomly
influenced only by allele population frequencies. Population-specific
differences thus include allelic heterogeneity; haplotype structure
variability; and differences in linkage disequilibrium patterns. LINGO1
has roles in oligodendrocyte development and axonal regeneration.
However, it is unknown if LINGO1 has any functional role in ET: the
GWAS SNP is intronic, and may be in linkage disequilibrium with an
actual functional genetic variant.13,14
Given the LINGO1 findings, some groups have explored sequence
variation and risk associations of related genes. A multicenter North
American effort utilizing 1,247 ET and 642 control samples combined
gene sequencing, association studies, and SNP haplotype tagging
across LINGO1 and the paralog LINGO2 to identify one LINGO2 SNP
associated with risk for ET under a recessive model (rs1412229).49 In
addition, two haplotype-tagged SNPs in LINGO2 (rs10812774,
rs7033345) influenced ET age of onset.49 A separate study in two
Asian cohorts comprising 327 total ET and 499 controls identified
different LINGO2 SNPs associated with ET (rs10812774) or ET and
Parkinson’s disease (PD) (rs7033345) risk, under recessive models.58
Reported LINGO2 risk associations are significant but relatively weak.
Potential associations with ET and genetic variants in the homolog
LINGO4 were not detected in 150 Chinese Han ET and 300 control
samples.59
While LINGO1 remains the strongest genetic risk finding for ET to
date (even with the overall mixed results), it is outside the reported ET
loci. The first reported specific ET-associated genetic variation,
828CRG in the HS1 binding protein 3 gene (HS1-BP3), is within
ETM2.60,61 While initial work pointed to a strong association between
this polymorphism and at least some ET,60,61 subsequent studies did
not confirm this association, arguing for at best a restricted role,
perhaps as a region in close linkage disequilibrium with a causative
mutation in some families.62,63 The HS1-BP3 828CRG variant was
not associated with either ET or PD risk in our cohorts.64 Within
ETM1, the dopamine D3 receptor (DRD3) gene (DRD3) 312ARG
variant is implicated in small, French ET families and in a case–control
analysis of US subjects: DRD3 genotype was associated with age of
onset and disease severity in these samples;65 an independent study of
Spanish subjects also observed an association with both ET risk and
ET age of onset.66 In contrast to these reports, replication studies in
Asian, Latvian, German, French, Danish, Italian, and at least two
independent US ET cohorts did not observe an association between
DRD3 variants and ET risk or ET age of onset,39,64,67–70 or linkage
with DRD3 in ET families.67,69 DRD3 is unlikely to play a role in ET
genetic pathophysiology.
There are numerous negative association studies based on potential
ET-like phenotypes within other disorders such as PD (including
leucine rich repeat kinase 2 LRRK2, and glucocerebrosidase GBA),
fragile X, and spinocerebellar ataxias, as well as a few unconfirmed
positive reports (microtubule-associated protein tau MAPT for
example).45,71–74 The discussion below focuses on hypotheses specific
to ET, and studies with independent follow-up.
One study observed an association between the length of a mixed
dinucleotide repeat sequence (REP1) in the gene encoding a-synuclein
(SNCA) and ET as well as PD.75 SNCA mutations and genomic
multiplications play a clear role in rare forms of inherited PD.76–82
REP1 allele length variants are associated with idiopathic PD in
multiple studies.75,83–89 However, a subsequent independent study of
SNCA and ET (Italian cohort) did not find an association between ET
risk and SNCA haplotypes.90 This study was unable to directly assess
the REP1 finding for various reasons, including issues with interpreting
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Table 1. Association Study Cohort Sizes in Essential Tremor (ET) Genetics Research




49 92 United States Negative
Shatunov et al, 200563
HS1-BP3 828CRG
variant
73 304 United States Positive
Higgins et al, 200661 Note initial 2005 report from same group with G
variant in ET cases in 2 of 21 US ET families, not ET
or unaffecteds in the other families, and not 150 US
controls or 73 ET Singaporean cases
HS1-BP3 828CRG
variant
222 132 United States Negative
Deng et al, 200562
ETM2
ETM2 sequence variants 30 30 Korean Positive
Kim et al, 200537
ETM2 polymorphisms 61 68 Czech Negative
Zahorakova et al, 201038
DRD3 312ARG variant 104 116 Latvian Negative
Inashkina et al, 200839
DRD3 312ARG variant 116 158 Italian Negative
Vitale et al, 200870
DRD3 312ARG variant 163 192 Singaporean Negative
Tan et al, 200768
DRD3 312ARG variant 201 282 Spanish Positive
Garcia-Martin et al,
200966
DRD3 312ARG variant 276 184 United States Positive
Jeanneteau et al, 200665 30 50 French
DRD3 312ARG variant 299 528 German, Danish,
French
Negative
Lorenz et al, 200969
DRD3 312ARG variant 433 272 United States Negative
Blair et al, 200867
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Table 1. Continued




109 430 Chinese Han Negative
Zuo et al, 201054
LINGO1 rs9652490 117 160 Chinese Negative
Wu et al, 201157 Note combining with Tan et al53
plus unpublished data into 307 ET and 804 control,
meta-analysis positive
LINGO1 rs9652490 141 130 Latvian Positive
Radovica et al, 201252 9 other SNPs including rs11856808 negative
LINGO4 variants 150 300 Chinese Han Negative
Liang et al, 201259
LINGO1 rs9652490 190 733 Singaporean Positive
Tan et al, 200953
LINGO1 rs9652490 and
rs11856808
226 1117 Spanish Negative
Lorenzo-Betancor et al,
201155
LINGO1 SNPs 257 265 United States Positive for rs9652490 and others
Clark et al, 201051 Negative for rs11856808 and
others out of 15 SNPs total




259 479 French Canadian Negative
Bourassa et al, 201156
LINGO2 variants 327 499 Chinese, Singaporean Positive for rs7033345 and rs10812774 of 8 variants
Wu et al, 201158
LINGO1 SNPs 332 574 German, French Positive for rs9652490 and 1 other
Thier et al, 201048 Negative for rs11856808 and
others out of 10 SNPs total
LINGO1 rs9652490 356 428 North American Positive
Vilarino-Guell et al,
201050
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REP1 lengths: the four dinucleotide repeats constituting REP1 all
varied; thus, alleles with identical lengths may represent varied
dinucleotide sequences instead of homozygous alleles.90 An extensive
study of SNPs across the SNCA locus in 647 ET and 1,285 control
samples did not show any associations with ET risk, although the
previously reported SNCA risk association with PD was replicated.91
Table 1. Continued
Study ET n Control n ET Cohort Source Overall Result
GWAS 452 14,394 Icelandic Positive for LINGO1 rs9652490 and
rs11856808 in initial cohort; rs9652490
only in confirmatory cohorts




1247 642 North American Positive for LINGO1 rs9652490 and 4 others of 16
total, and LINGO2 rs1412229 alone of 21.
Vilarino-Guell et al, 201049
SNCA
REP1 length 46 100 United States Positive
Tan et al, 200075
SNCA variants 106 90 Italian Negative
Pigullo et al, 200390
SNCA variants 647 1285 North American Negative










503 818 German, Dutch Negative
Thier et al, 201193
HNMT rs11558538 204 295 Spanish Positive
Ledesma et al, 200896
HNMT rs11558538 338 409 North American Negative
Keeling et al, 201097
Studies are grouped under genetic categories, and listed by first author and year of publication. Within hypothesis groups, studies are ordered by ET n. If the study
combined cohorts in one analysis then the full ET n is used. If the same study used different cohorts in different analyses, the larger ET n is listed first. ET cohort source
is geographical; some papers have further details on ethnicity. North American 5 United States and Canada. Overall result considers the main thrust of the study, with
a few further notations; see text for comments on age of onset influences, and cited references for full study results details including specific genetic variants tested,
haplotype analyses, methods.
Abbreviations: DRD3, dopamine D3 receptor gene; ET, essential tremor; ETM, Hereditary Essential Tremor, Online Mendelian Inheritance of Man (OMIM) locus
designation; GABA, gamma-aminobutyric acid; GABAAR, gamma-aminobutyric acid A receptor; HNMT, histamine N-methyltransferase gene; HS1-BP3, HS1 binding
protein 3 gene; LINGO, leucine-rich repeat- and Ig domain-containing Nogo receptor-interacting protein; numbered italicized LINGOs are genes encoding LINGO
proteins; REP1, mixed dinucleotide repeat sequence in the SNCA promoter region; SNCA, gene encoding a-synuclein; SNPs, single nucleotide polymorphisms; US,
United States.
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A mouse model of ET in gamma-aminobutyric acid A receptor
(GABAAR) alpha-1-subunit –/– mice has been proposed based on
face validity of the mouse phenotype.92 Subsequent human subject
studies have tested GABA and GABAAR genetic variants against ET
risk. Polymorphisms in 15 GABAAR and four GABA transporter
genes were investigated in German and Dutch cohorts. No evidence
for association with ET risk was observed.93 Variants in GABAAR
subtype genes were also not associated with ET risk studies in Spanish
samples.94,95
The histamine N-methyltransferase gene (HNMT) rs11558538
threonine allele, a functional variant, was nominated as an ET risk
factor.96 This result was not observed in a follow-up study by an
independent North American group.97
Challenges for genetics studies to date
Several inherent ET features complicate genetic linkage and
association studies (Table 2). This section reviews issues of phenoco-
pies and type 1 error, age dependence of phenotype expression and
type 2 error, tremor self-reporting, ET misdiagnoses, ranges of
phenotype that include mild tremor, and tensions between study
feasibility, sample size, and power.
High prevalence that increases with age and multiple distinct
susceptibility loci, together with a lack of information on possible
environmental determinants, all increase the possibility of phenocopies
within a family.22,36,98 Phenocopies are people with a similar or
identical phenotype due to different underlying genotypes or
environmental factors. Genetic linkage is based on the idea that a
given trait (phenotype) segregates with a distinct area and variant of
DNA (genotype). Even a single phenocopy has a large impact on the
LOD score, since in at least that phenocopy case (and possibly also
their descendants) the ET phenotype will not segregate or ‘‘link’’ to the
same locus as in the rest of the family. Given a 5% prevalence rate,
older family members will have a 1 in 20 possibility of ET by chance
alone. Spouses marrying in to the family have that same possibility of
having ET. There is already evidence for multiple loci in ET, making it
difficult to assume that spouses or even related affected family
members are not phenocopies. In association studies, phenocopies
represent false positives in the cases, potentially increasing type 1 error.
The age dependence of phenotype expression in ET has further
implications. Subjects of any age without tremor may simply be
presymptomatic. Controls too young to express their ET phenotype
become false negatives in association studies. Given that prevalence is
thought to increase with age, restricting controls to older ages at least
decreases this source of false negatives and type 2 error, although it
does not eliminate it. Incorrect unaffected status assignments in linkage
studies decrease the LOD score, much like unrecognized phenocopies.
Assuming no phenocopies within a family or case group, several
issues still directly impact results (Table 2). Early studies often relied on
self-reporting for tremor diagnosis, particularly for family members
thought to be unaffected. Self-reported family history may have poor
validity,99 and tremor self-reporting is often inaccurate;7,10,100–102 thus,
direct examination of all family members and controls is necessary for
accurate phenotype assignments. Self-reporting can introduce error via
misdiagnoses of significant tremor, and non-reporting of mild tremor,
as discussed below. Direct examinations of all subjects are critical for
data quality, but can be affected by ascertainment bias when not
blinded. On the other hand, individual research efforts may not have
the personnel to conduct assessments blinded to subject status as a
proband, family member, or unrelated control. Acquiring any
examination data, especially on controls, may be resisted on the basis
of cost. This is partially connected to a low awareness of the importance
of acquiring any tremor data in controls: the current National Institute
of Neurological Disorders and Stroke (NINDS) Coriell repository
control data set lists ‘‘essential tremor’’ under Other Medical History for
two of over 3,000 controls, well below population-based prevalence
estimates of 5%, and far below 23% mild undiagnosed ET in a study of
ostensibly healthy older controls.7 However, there is no specific
‘‘tremor’’ personal or family medical history question for the NINDS
repository, despite PD and dystonia questions, and a parkinsonism case
collection.103 PD studies will also suffer from lack of any basic systematic
tremor information on controls, as below.
Older family members are more likely to be taking medications,
potentially causing tremor, or have medical comorbidities like thyroid
disorders that cause unrelated tremors. More challenging are the
frequency and type of ET misdiagnoses. ET is a misdiagnosis in up to
30–50% of cases.104,105 The most common alternative diagnoses in
these series were PD and dystonia.104,105 Conversely, ET is frequently
misdiagnosed as PD.23,106 In the classic Hoehn and Yahr107 PD study,
39 of 856 subjects were excluded after determination of ET as their
correct diagnosis. Parkinsonism was incorrectly assigned to over half of
the cases in one nursing home study, based on a movement disorders
specialist review.108 Many patients carry a misdiagnosis for years.109
Setting aside current controversies in potential connections between
ET, PD, and dystonia, ascertaining a solid ET clinical diagnosis
contains enough uncertainty to potentially generate significant false-
positive and false-negative results, particularly when subject self-
reporting is used. Direct examinations using in-person movement
disorders expertise, along with video-recording as primary data instead
of examiner recall alone, can help reduce these error rates and greatly
improve genetics study data quality. As above, this high bar for
phenotyping data comes with costs in personnel and subject time.
In assigning status for genetic experiments, clinically relevant tremor
is only part of the spectrum of research relevant tremor. On the lower
end of tremor severity, it is impossible to distinguish enhanced
physiologic tremor (considered in the range of normal) from very mild
ET. ET subjects may transition from minimal hand tremor to
noticeable ET-like tremor without electrophysiological evidence of 8–
12 Hz physiologic tremor, implying that the initial tremor represents
early ET rather than a separate entity.110 Research definitions may
conflict with community needs and understanding: family members
with mild ET may self-report no tremor, or at least resist an affected
label as they do not consider themselves to have a clinical diagnosis. At
the same time, tremor in ET has long been recognized as
progressive.10,25 This includes the phenomenon of longstanding mild
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Table 2. Consequences of Basic Essential Tremor (ET) Features Create Challenges for ET Genetics Research. The current ET clinical definition has a direct impact on ET
research. Ways to move forward acknowledge and address these challenges.
Current ET
Feature









Increased type 1 error






data (see also Table 3).
Use inclusive varied
phenotype as outcome
rather than narrow ET
definition.





possible phenotypes may or
may not increase genetic
homogeneity within groups.
Research definitions, specify ET subsets, accept
potential even ‘‘non-ET’’ phenotype variables as
part of hypotheses generation and testing, use
phenotype variables across clinical diagnoses.
Experimental design goals are to broaden
testable hypotheses, thus move past the
















Lowers impact of this error
type but does not eliminate it.
Prospective studies of age of onset may change
perspective on this ET feature.
Large collaborative efforts particularly on
control data and family member data help
improve power and get past this ET feature.

















Direct exams of all
subjects: case, control,
family member
Larger sample sizes to





analysis to definite cases
Detailed longitudinal
phenotyping requires high
investment in time and funds.
Both subject and researcher
resources impact feasibility
of extended direct exams.
Large sample sizes are
expensive and time
consuming to collect.
There is always uncertainty
in a clinical diagnosis,
especially with mild tremor,
and comparing to other
clinically defined movement
disorders.
Some level of mechanistic
heterogeneity likely in all
case and control groups.
Collaborative efforts between: multiple centers;
movement disorders experts and genetics
experts; researchers and ET research participants.
Collaborative efforts to define minimal and
additional phenotype data, minimal and
additional biosample amounts and time points.
Explicit review of feasibility versus data quality
tradeoffs to understand choices for each
experiment: Non-blinded exams may cause
ascertainment bias; time burden for subjects may
limit phenotype data; scoring videos rather than in
person exams may lower some phenotype data
quality but improve blinding and allow multiple
examiners; definite-only ET case definition may
strengthen result but impact power.
Use experimental design process to broaden
range of testable hypotheses as above.











































hand tremor morphing after years to decades into symptomatically
significant typical ET that prompts diagnosis and treatment.10,25,111 In
our own research cohort, 12 of 38 members in one family self-reported
no tremor but had tremor on examination, including cases of definite
ET and cases who would acknowledge ‘‘nervousness’’ rather than
tremor.112
One approach is to utilize a possible/probable/definite scheme for
ET research diagnosis,18,113 as in the twin study above.16 At least three
of the association studies above restricted ET cases to TRIG criteria
definite48,90 or probable and definite ET.91 This has obvious
implications for achieving higher sample size case groups (Table 2).
The tension between reducing false-positive/negative rates, ET
research diagnoses, and feasibility considerations can be seen in
Table 1, a listing of association studies by general genetic category and
ET cohort size. While control group sizes also matter, in most studies
there is even less information on controls than cases. With the
exception of LINGO genes, in general small sample size studies report a
positive result that over time moves to larger sample sizes and negative
outcomes. Note also larger cohorts are weighted to Western European
and North American sources, which are heavily self-reported
Caucasian or White, with limited ethnic variability, although there
are some data on Ashkenazi Jewish subjects and rare African-
American subjects.51,91
The Shatunov et al36 ETM3 linkage study restricted affected
status to definite ET in directly examined subjects, and considered
all other family members unknown. This stringent approach deals
with age dependence of tremor expression, and the uncertainties in
both mild tremor and ET misdiagnosis (Table 2). It also imposes a
high burden on achieving enough power to detect a potential
locus.
Fundamental assumptions and ET genetics research
Many genetics studies report no information on how ET is
determined, little information on subject cohort characteristics beyond
number of ET versus controls, and little to no information on how
terms like ‘‘familial’’ and ‘‘sporadic’’ ET are defined. Linkage
experiments vacillate between lack of solid data for accurate subject
status assignments and loss of power; association studies often use very
small sample sizes and less expensive but less informative techniques
like studying a single SNP. These issues, discussed above, impact the
ability to detect ET causal mutations and genetic risk associations in
studies to date (Table 2). We can do better on the basics: many groups
already are. Is that enough? Conceptualizing ET as a family of
primarily genetic disorders and improving the quality of basic work has
moved the field forward, but only so far. Past ET genetics studies
largely work under two sets of assumptions: definition choices framing
ET as a phenotypically homogeneous disorder; and genetics experi-
ment structures based on straightforward Mendelian autosomal
dominant inheritance of common genetic variants. Current key
challenges involve shifting fundamental assumptions to create further
progress in the field (Table 3).
From the movement disorders side: defining the ET phenotype
Even the best ET work contends with assumptions underlying all
clinically defined complex disorders: the clinical definition is known,
and the clinically based definition relates to underlying pathology. An
excellent treatment by MacMahon and Pugh114 notes ‘‘The disease
entities … have been selected, from the innumerable possibilities … on
the basis of usefulness for prevention or treatment or on the basis of
medical tradition.’’ To begin to organize clinical care, definition
decisions must be made based on disease manifestation, which is
sometimes a matter of tradition rather than data. One only assumes
that ‘‘arrangements of ill persons by their manifestations may identify
groups that have at least some degree of homogeneity with respect to
causal factors … a useful basis for investigation of cause.’’114
The spectrum of ET phenotype and pathology are still open
questions, creating opportunities to re-examine current clinical ET
definitions, particularly that of a monosymptomatic homogeneous
clinical picture.18,115,116 Even a clinically useful definition is not
necessarily useful for research on disease mechanism. Phenotype
definition issues relevant to ET genetics research include whether and
how to use tremor age of onset, motor symptoms beyond action
tremor, non-motor symptoms, and phenotypes closely overlapping
with other clinically defined movement disorders.
Starting with monosymptomatic kinetic tremor as ET, a proposed
ET research variable is early age of onset. As an example, LINGO
gene variants may influence ET age of onset, or be more strongly
associated with early age of onset cases.14,49,51 However, retrospective
age of onset represents fairly weak data in ET. Patients often report the
age when tremor became noticeable or bothersome as their age of
onset, discounting the ‘‘nervousness’’ or mild tremor noted from a
young age.10 Prospective age of onset studies will require extended
longitudinal follow-up of large varied cohorts. In the meantime,
clarifying ways to obtain age of onset as research data, or working
within the small subset of cases with moderate to severe tremor at an
early age, could strengthen the use of this proposed characteristic.
The debate becomes more interesting when research moves away
from monosymptomatic kinetic tremor. Are there other motor, and
non-motor, ET features? Are there mechanistic connections between
ET and other disorders? These are areas of intense opinion. They are
considered here in the context of ET genetics research design,
advocating moving past binary clinical label phenotype data (Table 3).
The idea of formally dividing ET into classic and ‘‘complicated’’
cases, usually ET–parkinsonism or ET–dystonia, dates back to at least
the 1800s.10,115,116 Early attempts to clearly separate ET and PD also
acknowledge ‘‘exceptional cases’’ that could represent an ET–
parkinsonism overlap.10 Researchers may therefore have to make
definition choices discordant from clinical ones, or be more agnostic
about which features are ‘‘allowed’’ in research phenotypes. Exploring
ET in a research context may require using ET subsets within or
beyond clinical diagnoses. Whether or not clinical ET exists in subsets,
use of ET subsets and broader phenotyping parameters may be useful
for research.
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Table 3. Moving Past Underlying Assumptions in Essential Tremor (ET) Genetics Research. Many research groups are responding to early
assumptions about ET with new approaches and theories. This process uncovers further challenges to advancing ET genetics research.
Assumption Possible Responses Challenges Moving Forward
ET is a simple,
known
phenotype
















ET is tremor in isolation by clinical
definition
May not be currently useful, often ill
defined.
Retrospective data, large differences in
actual tremor age of onset versus
bothersome increased tremor symptoms
reported as age of onset.
ET is tremor in isolation by clinical
definition
ET and PD may or may not be related
disorders; ET and PD are common
mutual misdiagnoses.
ET is tremor in isolation by clinical
definition; ET and PD may or may not be
related disorders
Isolated head tremor is ET by clinical
definition, but could be cervical dystonia;
ET and limb dystonia misdiagnoses versus
ET plus dystonia in non-tremor area.
Use of research phenotype features
rather than clinical diagnosis criteria
If ‘‘familial’’ subset used, clear definition
with how family history data obtained.
Longitudinal prospective data would
strengthen this considerably.
Use of research phenotype features
rather than clinical diagnosis criteria.
Record ET, PD, and dystonia exam
features; then able to exclude ET-PD or
dystonia cases from genetics studies, or
focus on an ET-PD, ET-parkinsonism, or
ET-dystonia subset depending on
hypothesis.
Longitudinal prospective studies with
neuropathology will best address
research questions.









variants, alone and in
combination, are




Detecting different types of genetic risk
factors and causal mutations
Addressing non-mendelian inheritance at
a complex biological data level
Collaborative phenotype-genotype
studies with multiple research groups to




genetic sequencing (exome, genome),






















ET community concerns may not be
relevant to phenotype-genotype
experiment design.
How to return complex genetic data
information to research subjects is not
straightforward.
Understand ET community research
goals, ET subject observations about ET
phenotype and inheritance.
Improve education of ET community on
goals and results of genetics research,
to increase motivated informed
participation in genetics research
studies.
Abbreviations: ET, essential tremor; PD, Parkinson’s disease.
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The ongoing attempts to untangle ET and PD117–119 can be viewed
from a genetics research perspective. Pragmatically, cases with both
ET and PD (ET–PD) are well reported. Whether ET–PD represents
individuals fortunate enough to have two common entities by chance,
or one underlying mechanism evolving from an ET to an ET–PD
phenotype, specifying how parkinsonism and PD is determined in ET
cases and eliminating ET–PD cases from ET groups is important (see
Ross et al91 for one example) but far from standard in ET genetics
work.118 Focusing specifically on ET–PD compared with ET or PD
alone, or ET–PD families rather than cases,120 may help settle points
of debate. Research groups are already looking for genetic connections
between ET and PD, at both association and family study levels, with
mixed results.15,49,91,118–122 Specific families with apparent coinheri-
tance of ET and other defined disorders, such as PD,120 PD and
restless leg syndrome,123 or idiopathic normal pressure hydrocepha-
lus,124 may yield rare variant information.
Features beyond kinetic tremor may be part of the ET phenotype
itself, not an indication of ET plus a second disorder. Some level of
parkinsonism, not PD, may be clinically acceptable in ET. Minimal
parkinsonian signs without clinical PD are frequently reported,
including mild changes in tone with cogwheel rigidity, and mild arm
swing decrease.23,25,112,115,116 Severe kinetic tremor may break up
fine motor tasks, creating clumsiness symptoms and impaired fine
motor testing. Rest tremor is documented in ET, notably in indi-
viduals with longstanding severe classic ET in whom the rest tremor
component is less severe than kinetic/posture tremor.112,125–127 Rest
tremor in ET may be observed without any other parkinsonian
signs.112,125–127 Specifying parkinsonism features as part of minimal
ET phenotyping allows investigators to test a range of hypotheses:
that all ET cases share an underlying cause and should be included in
the same cohort; that cases with any parkinsonism features should be
excluded to improve phenotype and presumably genotype homo-
geneity; that ET–parkinsonism cases are an informative subset with
distinct causal mechanism(s).
A related approach is to use phenotype variables instead of disease
diagnosis as the outcome against genetic predictors. For example, a
genetic variant could be tested against a tremor feature, within ET or
regardless of ET or PD clinical diagnosis. As an illustration of
principle, asymmetric tremor severity is often observed in PD,
although not all PD cases have any tremor. The ET clinical definition
includes both upper extremity tremor in isolation, and head tremor in
isolation.18,115,128 ET versus PD genetic papers rarely comment on
whether PD cases were tremor predominant, or if ET cases include
those with head tremor alone. Current clinical definitions stress
bilateral upper extremity tremor in ET with unilateral tremor as a red
flag indicating an alternative diagnosis, but tremor severity in ET may
be asymmetric,24,129 and many descriptions of ET note frequent
unilateral onset with eventual (2–3 years) spread to both upper
extremities.10,19,23,25 Asymmetric severity and unilateral tremor onset
may predict greater ET progression.130 Asymmetric tremor severity, or
even just the presence of upper extremity tremor, can be tested against
genotypes within or between ET and PD cohorts. As above, outward
tremor features may or may not indicate underlying mechanistic
connections: when hypotheses are structured around phenotype
variables instead of diagnoses, the door is open to either outcome.
Non-tremor features of ET are also rarely explored in genetics
research. Clinical scales focus on tremor, often biased to upper
extremity kinetic tremor. Mild imbalance manifesting as impaired
tandem gait is common in ET.131–134 ET subjects have significant
impairments on multiple measures of postural control and functional
mobility, independent of tremor body area (head or no head tremor)
and tremor severity.135 Dystonia as an ET motor feature is considered
below. Non-motor features such as mood and cognitive changes are
under ongoing study but are not considered a clear part of clinically
defined ET.136 Genetic risks could be tested against any of these
outcomes, again within ET or across ET and other clinically defined
groups. This adds both richer information and more flexibility to
research designs. Major challenges to this approach are agreeing on
phenotype variables across research groups, having sufficient power to
address multiple testing issues, and addressing subject burden as
research participation time increases. Regarding agreement on
phenotype datasets, testing hypotheses in this type of structure does
not commit the clinical ET definition to change, or imply that
phenotype variables are clearly part of ET. It improves the ability to
explore a range of possible outcomes, whether ET and other disorders
share mechanistic connections or not—or whether phenotype-variable
subsets do a better job representing genotypes than diagnosis subsets,
or not.
Dystonia and ET is another contested area of potential mechanistic
connection, with some genetics data behind it. Concurrent dystonia is
an exclusion criterion in the current ET clinical diagnosis.18,115,128 On
the other hand, head tremor in isolation is considered clinical ET, but
cervical dystonia often causes head tremor. As above, ET genetics
studies rarely record whether ET cases include head tremor, arm
tremor, or both; nor do they generally specify if dystonia was
specifically queried or examined. Dystonia is therefore a source of ET
misdiagnoses, i.e., false positives. More interesting is considering
dystonia as a potentially useful phenotype variable. Tremor and
dystonia can occur in separate body areas. A relevant example is ET-
like arm tremor with cervical dystonia, a phenotype of highly contested
classification (see Schiebler et al137 for review). Dystonia in a non-
tremor area may develop long after the tremor, reinforcing how
longitudinal information about disease course is important in forming
ET subsets.137 Outside of the ET clinical definition debate, there is
movement towards recognizing (by any label) ET and dystonia, or
recording specific variables such as arm tremor, head/neck tremor,
and cervical dystonia. These arguments parallel the PD and tremor
examples above. For dystonia, motivation to change ET research
approaches also comes from genetics.
Phenotypes can be considered at the pedigree as well as the
individual case level. In the ETM3 linkage study, dystonia was not only
specifically recorded for all family members; the 6p23 locus was only
linked in families with a mix of dystonia and ET.36 A detailed ET
phenotype study utilizing in-person movement disorders examinations
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of all probands and family members observed multiple cases of
dystonia, with or without ET in each individual case, in 28% of 97 ET
kindreds.138 This provides further motivation for an ET–dystonia
subset. As in ET–PD or ET–parkinsonism, the hypothesis is that
pedigree-level ET subsets can reflect underlying genotypes in some
cases.
What if kinetic arm tremor plus cervical dystonia isn’t ‘‘real’’ ET?
We do not know what real ET will be in a future, more causal
mechanism-driven definition set. Currently we assume ET clinical
definitions match underlying disease mechanisms. Any ET research
phenotype choice could increase rather than decrease genetic
heterogeneity compared with an ET clinical diagnosis group.
Conversely, one genotype may cause a wide range of phenotypes
(Tables 2 and 3). This challenge can be experienced as a stalemate,
where any phenotype choice is equally wrong, as we do not yet know
phenotype–genotype connections. Instead, using a rich, open pheno-
typing approach broadens the range of testable hypotheses, including
whether or not a given phenotype is related to a genotype, or
ultimately to a clinical diagnosis. A shift from binary ET diagnosis
outcome based on limited clinical criteria to research-oriented
phenotypes generates progress by opening up possibilities in genetics
experiment design.
The conceptual shift in ET phenotyping is reflected in research
techniques. In addition to more videotaped detailed examination data,
and use of validated scales across tremor and non-tremor features,
investigators are incorporating objective measures such as digitized
spiral analysis, electromyography, and accelerometry recording (see
Shatunov et al36 for example). Calls for longitudinal detailed ET
phenotype cohort studies with neuropathological follow-up are well
founded:117,139 such studies would greatly enhance ET genetics work
by providing the level of phenotype data needed, tied to neuropatho-
logical diagnosis as well as clinical diagnosis. Phenotypically homo-
geneous criteria are driven clinically, not by biomarkers or other
reliable gold standards. Neuropathology is the gold standard diagnosis
for PD, although not ET or dystonia; still this is a way to greatly
enhance data used for decision making in genetic sample analyses.
Improving ET phenotyping includes basic issues such as direct
examination of research subjects. Redefining ET phenotyping
encompasses incorporating a range of motor, non-motor, examina-
tion, objective measure, prospective, longitudinal, and neuropatho-
logical data into a rich, fruitful resource. New approaches to ET
phenotyping will enable ET research to fully exploit advancing
genetics technologies.
From the genetics side: mechanism of inheritance
Working within a genetic framework, the ET field is already
moving into new ways to detect and analyze patterns of disease-
associated change. ET was originally conceptualized as a phenotypi-
cally homogeneous familial entity, caused by common genetic
variants. ET is better characterized as a complex trait;14,121
pathophysiology could therefore involve rare genetic variants in
combination, instead of a few common variants.121,140–143 As reflected
by the association studies in ET (Table 1), the field is moving from
single genetic variant analysis to more detailed, comprehensive
sequencing approaches of candidate areas or the genome. While ET
genetics thinking has already started to shift, integrating new
phenotyping approaches and use of different phenotyping datasets
against genotype data remain rare. This section outlines key ET
challenges from the genetics side: whether and how to distinguish
familial and sporadic ET; ET mechanisms of inheritance; and moving
into new genetics technologies.
Genetic research reports often distinguish between ‘‘familial’’ and
‘‘sporadic’’ ET, even though this distinction is considered supporting
not primary data for clinical definition,18 and is not currently clinically
useful. Is the assumption that ET can be divided into familial and
sporadic cases useful for research? A mix of familial and sporadic
disease in a cohort could certainly affect attempts at genetics research:
LINGO1 results may be stronger in familial ET.14 However, it is often
unclear what these terms mean in ET. There is little consensus on
whether studies should focus in on subjects with an extensive, clear
family history, or not—or what constitutes extensive or clear. Many
issues make ET family history challenging to interpret: ‘‘senile tremor’’
is dismissed by patients and providers, mild tremor may be unknown
to other family members, ET is often misdiagnosed, direct examina-
tions of all family members may be appropriate but not feasible. Given
these issues plus the tremendous percentage of positive family history
in studies discussed above, one valid approach is to disregard sporadic
and familial subsets as not useful at this time.26 An alternative is to
rank the quality of family history, where a conservative definition of
positive family history may hinder acquiring large sample sizes and
exclude informative cases, but improve overall data quality and help
focus genetics work on a potentially powerful ET subset.
Even with the above caveats, the well-reported high rate of positive
family history is an obvious starting point for ET research. There is
varied and convincing evidence that much of ET is inherited in an
autosomal dominant fashion,45,144 although complex multigenetic
modes of inheritance cannot yet be excluded.22,36,45,116,145 The field
has already moved into deep sequencing both coding and non-coding
DNA stretches, or utilizing full exome strategies: in the first case with
mixed results, and in the latter with conspicuously silent results. This
could reasonably be blamed on the unfortunate wealth of inherent ET
phenotype issues discussed above (Table 2), as well as natural shaking
out of replication attempts from early smaller studies. Another factor
may be a main feature of ET: assumptions based on pedigree
appearances of a highly prevalent and penetrant autosomal dominant
disorder (Table 3).
The high number of affected individuals in ET families was initially
attractive to research groups. The high prevalence and high rate of
affected family members, while potentially challenging for genetics
studies, were not considered an indication of primary mechanism.26
For example, the ET parish study concluded that chance variations in
previous generations when the parish population was very small were
enough to account for the high phenotype and thus assumed high
genetic variant frequency25. As more and more familial linkage studies
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returned negative results, some suspected ‘‘too many’’ affecteds for a
straightforward autosomal dominant mechanism.145 A combination of
phenocopies, ascertainment bias, and non-ET tremors (physiologic
tremor, PD, medications) could explain the high reported affected
numbers, as above. A non-Mendelian inheritance pattern presents an
alternate explanation.98
Epigenetics encompasses mechanisms that change gene expression
or activity without changing DNA sequences: DNA methylation and
histone modification are classic examples. Epigenetic states can, at
least in part, be inherited.146 This type of inheritance can occur in
humans, through unclear mechanisms (reviewed in Zimprich98).
Epigenetic variation would not be detected by genome sequencing
experiments. In a recent hypothesis paper, Zimprich details how
epigenetic inheritance could explain observations in ET.98 An
epigenetic feature may be transmitted from one allele to another in
a parent cell prior to meiosis; thus in the gametes both the disease-
causing allele and the originally benign allele become disease causing.
This is termed paramutation.147 Long described in plants, the role of
paramutation in mammals, particularly humans, is postulated from
observations in diabetes mellitus but is uncertain.98,148 Zimprich puts
forward a framework of primarily epigenetic and paramutation
inheritance, rather than genetic state, accounting for ET pedigree
phenotype patterns.98 This intriguing theory pushes the field to
consider diverse mechanism options. Pursuing this theory will require
advances in detecting and analyzing epigenetic changes; for example,
‘‘methylome’’ analysis.149
Another alternate explanation of ET inheritance remains within
genetics: ET may be a complex trait, with work to date identifying only
a limited amount of the heritable component of ET.15,22,36,45,116,121,145
Uncovering ‘‘missing heritability’’ in ET may require researchers to
pursue rare rather than common causal genetics variants, and/or
many genetic risk factors.15,121,140 As in epigenetics, progress in
genetics is often made through advancing technologies. Next-
generation sequencing allows sequencing the whole genome, for
example from members of one pedigree in an attempt to identify a
causal mutation. High-throughput sequencing can be restricted to
exons (exome sequencing).150 New sequencing technology holds great
promise for testing the theory that ET is a complex trait caused by
combinations of rare genetic variants, rather than a family of disorders
caused by a small number of common causal mutations. Experiments
utilizing next generation sequencing to achieve detailed analysis across
coding, intronic, and regulatory areas could help detect rare genetic
variants contributing to ET.15,121,140–142
Advances in analyzing large datasets will also be crucial. This can be
considered across a spectrum of genetic data: rare variants with a high
impact on disease causation, low-frequency genetic variants with
intermediate effects, and combinations of relatively common variants
acting as genetic risk factors each with a small effect size.140,151
Already, meta-analyses leveraging multiple independent GWAS
datasets in PD have set an example for detecting genetic risk factors
with small effect sizes.151 Considering genetic and environmental risk
factor data together is another potentially fruitful approach152 that
demands advances in large dataset analyses.
New sequencing technologies are also necessary for detecting the full
range of genetic variants that may contribute to ET. Structure variants
are not single nucleotide (SNP) changes; instead the term encompasses
various changes such as insertions, deletions, and DNA sequence
inversions.140 One structural variant form is copy number variants:
DNA stretches that are usually unique are repeated, in duplicate or
triplicate. Their size in base pairs varies widely. Efforts focusing on
specific genetic regions have uncovered copy number variant effects in
movement disorders such as PD and chorea–acanthocytosis.153,154
New array technologies are greatly expanding the ability to detect copy
number variants.155 Detecting copy number and other structural
variants on a large scale is hampered by sequencing technology
limitations, cost, statistical power issues, and challenges in interpreting
the clinical significance of observed variants.140,155
Genetic approaches will benefit from lowering costs and advances in
epigenetic methods, high-throughput sequencing, and high-dimen-
sional data analysis. For ET genetics research, progress will come as
much from evolving phenotype work as new ‘‘-omics’’. Contributions
from both the genetics and the movement disorders sides position the
field to meet ET research challenges.
Moving forward
Collaborators in movement disorders and genetics are rethinking
fundamental assumptions and experimental designs to better advance
knowledge in the field (Table 3). This includes using a range of
phenotype outcomes from clinical diagnosis labels and ET subsets to
phenotype data points within or across ET, PD, and other disorders.
Gathering detailed prospective longitudinal phenotype data instead of
clinical opinion on diagnosis or retrospective record review represents
a significant shift in culture. Video-recording examinations, even if the
in-person data are the outcomes, so the primary data are the actual
examinations not the opinion of the examiner, is becoming standard;
whether video rating rather than in-person rating is sufficient for all
studies is an open question. In rethinking genetic approaches, the field
is already moving on: examples include efforts at expanding
collaborations36,49,91; considering intronic46,90,91 and regulatory90,91
as well as coding regions; utilizing a variety of linkage and association
analysis techniques.36,49,51,91 To some extent, genetics efforts are also
moving on from older phenotype strategies: for example, using definite
ET for affected status,16,36,48,90,91 and including data on dystonia.36
Overall, investigators are considering how to test novel hypotheses to
account for observations in ET: how to detect rare genetic variants
contributing to a complex disorder, or epigenetic changes contributing
to different modes of inheritance; how to test different phenotype
structures against genotypes.
The biggest shift may be moving from debates about phenotype or
genotype in isolation to how to attack the interactions between the two.
In ET genetics research, the days of handing over or accepting an
isolated set of de-identified samples labeled ET or control are over.
Collaboration now means considering both phenotype and genetic
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technique choices together, with input from the movement disorders
and genetics sides. Moving beyond assumptions in the field creates new
challenges; for example, finding a balance between communicating
about experiment design before samples and phenotype data are
collected, and allowing flexibility for advances in genetics technology,
data analysis, and phenotype definitions over time. As in many slowly
progressive later onset disorders, a central balancing act is between
cost versus phenotype data detail, range of prospective data time
points, types of genetics sample processing, and ability to analyze high
dimensional data. We can take encouragement from successful
examples in Huntington disease156 and PD157–159 when advocating
for the level of ET phenotype–genotype work necessary to create
scientific advances in the field.
Some issues, like ethical and pragmatic consideration in sharing
biosamples, affect genetics work in many areas. Given results to date,
working through these hurdles represents an acute challenge in
ET.121 The most recent locus, ETM3, represented work across
several groups;36 the GWAS required input and multiple confirma-
tory cohorts from collaborators.46 Of the association studies reviewed
in Table 1, the only ones above an ET n of 50091 or 100049 were
from the start of a North American Essential Tremor Consortium
collaborative effort in ET genetics, which grew out of the TRIG and
now includes over 14 groups. We hope to contribute more results
across many more consortium members, and encourage other groups
to do the same.
These kinds of studies are necessarily collaborative. A key element in
these collaborations is the research subject community (Table 3).
Patients and families volunteer their time, information about
themselves and family members, and biosamples. ET patients and
families are often highly motivated to participate in genetics research,
and are beginning to organize from a research participant perspective.
How and when to return genetic research data to subjects and families
is a general topic in genetics,155,160 and as yet unexplored in ET. How
to effectively include participation from subjects with a range of ethnic
backgrounds in the context of rigorous genetics design, particularly in
North American work, is also an underdeveloped area.
Conclusions
In summary, lack of an ET biomarker is a challenge to the research
community, not a stalemate. Increased understanding of ET genetics
will be an important step in ET biomarker development. Large
collaborative efforts including genetics and movement disorders
expertise are forming. We are only beginning to engage the patient
and family community central to the research on a collaborative level.
The ability for multiple groups to generate and analyze detailed
genetic data under varied experimental models is increasing: work is
still critically needed on minimum phenotyping datasets that can be
consistent across many groups in prospective studies, but at the same
time are well beyond a binary clinical diagnosis. In the end, we may
experience a major shift in ET and beyond as we uncover mechanisms
behind movement disorders manifestations: ‘‘causal factors of disease,
when identified, not uncommonly have effects that cross the
boundaries of adjacent manifestational groups … Change from a
manifestational to a causal axis of classification may result in a major
regrouping of impaired individuals.’’114 Despite the hurdles, it is an
exciting time in the field, when researchers have the opportunity to
find new ways to work together towards progress in an important and
wide-open area.
Acknowledgements
The author thanks the essential tremor patients and families who
inspire and drive the research in this field; and North American
Essential Tremor Consortium and Tremor Research Group colleagues
whose commitment to collaborative research moves the field forward.
References
1. Dogu O, Louis ED, Sevim S, Kaleagasi H, Aral M. Clinical
characteristics of essential tremor in Mersin, Turkey: A population-based
door-to-door study. J Neurol 2005;252:570–574, doi: http://dx.doi.org/10.
1007/s00415-005-0700-8.
2. Rajput A, Robinson CA, Rajput AH. Essential tremor course and
disability: A clinicopathologic study of 20 cases. Neurology 2004;62:932–936, doi:
http://dx.doi.org/10.1212/01.WNL.0000115145.18830.1A.
3. Louis ED, Barnes L, Albert SM, et al. Correlates of functional disability in
essential tremor. Mov Disord 2001;16:914–920, doi: http://dx.doi.org/10.1002/
mds.1184.
4. Sullivan KL, Hauser RA, Zesiewicz TA. Essential tremor. Epidemiology,
diagnosis, and treatment. Neurologist 2004;10:250–258, doi: http://dx.doi.org/
10.1097/01.nrl.0000138736.07840.b2.
5. Louis ED, Ferreira JJ. How common is the most common adult
movement disorder? Update on the worldwide prevalence of essential tremor.
Mov Disord 2010;25:534–541, doi: http://dx.doi.org/10.1002/mds.22838.
6. Dogu O, Sevim S, Camdeviren H, et al. Prevalence of essential tremor:
door-to-door neurologic exams in Mersin Province, Turkey. Neurology 2003;61:
1804–1806, doi: http://dx.doi.org/10.1212/01.WNL.0000099075.19951.8C.
7. Elble RJ. Tremor in ostensibly normal elderly people. Mov Disord 1998;13:
457–464, doi: http://dx.doi.org/10.1002/mds.870130314.
8. Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin
1996;14:317–335, doi: http://dx.doi.org/10.1016/S0733-8619(05)70259-0.
9. Lyons KE, Pahwa R, Comella CL, et al. Benefits and risks of
pharmacological treatments for essential tremor. Drug Saf 2003;26:461–481,
doi: http://dx.doi.org/10.2165/00002018-200326070-00003.
10. Critchley M. Observations on essential (heredofamial) tremor. Brain
1949;72:113–139, doi: http://dx.doi.org/10.1093/brain/72.2.113.
11. Louis ED, Broussolle E, Goetz CG, Krack P, Kaufmann P, Mazzoni P.
Historical underpinnings of the term essential tremor in the late 19th century.
Neurology 2008;71:856–859, doi: http://dx.doi.org/10.1212/01.wnl.
0000325564.38165.d1.
12. Dana CL. Hereditary tremor, a hitherto undescribed form of motor
neurosis. Am J Med Sci 1887;94:386–393, doi: http://dx.doi.org/10.1097/
00000441-188710000-00005.
13. Tan EK. LINGO1 and essential tremor: linking the shakes. Linking
LINGO1 to essential tremor. Eur J Hum Genet 2010;18:739–740, doi: http://dx.
doi.org/10.1038/ejhg.2010.25.
Testa CM Essential Tremor Genetics Research Challenges
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services14
14. Jasinska-Myga B, Wider C. Genetics of essential tremor. Parkinsonism
Relat Disord 2012;18:S138–139, doi: http://dx.doi.org/10.1016/S1353-
8020(11)70043-8.
15. Zimprich A. Genetics of Parkinson’s disease and essential tremor. Curr
Opin Neurol 2011;24:318–323, doi: http://dx.doi.org/10.1097/WCO.
0b013e3283484b87.
16. Lorenz D, Frederiksen H, Moises H, Kopper F, Deuschl G, Christensen
K. High concordance for essential tremor in monozygotic twins of old age.
Neurology 2004;62:208–211, doi: http://dx.doi.org/10.1212/01.WNL.
0000103236.26934.41.
17. Tanner CM, Goldman SM, Lyons KE, et al. Essential tremor in twins:
an assessment of genetic vs environmental determinants of etiology. Neurology
2001;57:1389–1391, doi: http://dx.doi.org/10.1212/WNL.57.8.1389.
18. Deuschl G, Bain P, Brin M, and the Ad Hoc Scientific Committee.
Consensus statement of the Movement Disorder Society on Tremor. Mov Disord
1998;13:2–23, doi: http://dx.doi.org/10.1002/mds.870131303.
19. Whaley NR, Putzke JD, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor:
phenotypic expression in a clinical cohort. Parkinsonism Relat Disord 2007;13:333–
339, doi: http://dx.doi.org/10.1016/j.parkreldis.2006.12.004.
20. Koller WC, Busenbark K, Miner K. The relationship of essential tremor
to other movement disorders: report on 678 patients. Essential Tremor Study
Group. Ann Neurol 1994;35:717–723, doi: http://dx.doi.org/10.1002/ana.
410350613.
21. Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients.
Neurology 1991;41:234–238, doi: http://dx.doi.org/10.1212/WNL.41.2_Part_1.
234.
22. Louis ED, Ottman R. How familial is familial tremor? The genetic
epidemiology of essential tremor. Neurology 1996;46:1200–1205, doi: http://dx.
doi.org/10.1212/WNL.46.5.1200.
23. Critchley E. Clinical manifestations of essential tremor. J Neurol
Neurosurg Psychiatry 1972;35:365–372, doi: http://dx.doi.org/10.1136/jnnp.
35.3.365.
24. Dotchin CL, Walker RW. The prevalence of essential tremor in rural
northern Tanzania. J Neurol Neurosurg Psychiatry 2008;79:1107–1109, doi: http://
dx.doi.org/10.1136/jnnp.2007.134304.
25. Larsson T, Sjogren T. Essential tremor: a clinical and genetic population
study. Acta Psychiatr Scand Suppl 1960;36:1–176.
26. Busenbark K, Barnes P, Lyons K, Ince D, Villagra F, Koller WC.
Accuracy of reported family histories of essential tremor. Neurology 1996;47:264–
265, doi: http://dx.doi.org/10.1212/WNL.47.1.264.
27. Louis ED. Essential tremor. Lancet Neurol 2005;4:100–110, doi: http://dx.
doi.org/10.1016/S1474-4422(05)00991-9.
28. Elble RJ. Diagnostic criteria for essential tremor and differential
diagnosis. Neurology 2000;54:S2–6, doi: http://dx.doi.org/10.1212/WNL.54.1.
2.
29. Findley LJ. Epidemiology and genetics of essential tremor. Neurology
2000;54:S8–S13, doi: http://dx.doi.org/10.1212/WNL.54.1.8.
30. Morton NE. Sequential tests for the detection of linkage. Am J Hum Genet
1955;7:277–318.
31. Gulcher JR, Jonsson P, Kong A, et al. Mapping of a familial essential
tremor gene, FET1, to chromosome 3q13. Nat Genet 1997;17:84–87, doi:
http://dx.doi.org/10.1038/ng0997-84.
32. Illarioshkin SN, Rakhmonov RA, Ivanova-Smolenskaia IA, et al.
Molecular genetic analysis of essential tremor. Genetika 2002;38:1704–1709.
33. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to
chromosome 2p22–p25. Mov Disord 1997;12:859–864, doi: http://dx.doi.org/
10.1002/mds.870120605.
34. Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for
essential tremor maps to chromosome 2p in four families. Mov Disord 1998;13:
972–977, doi: http://dx.doi.org/10.1002/mds.870130621.
35. Higgins JJ, Lombardi RQ, Pucilowska J, Ruszczyk MU. Integrated
physical map of the human essential tremor gene region (ETM2) on
chromosome 2p24.3–p24.2. Am J Med Genet B Neuropsychiatr Genet 2004;127:
128–130, doi: http://dx.doi.org/10.1002/ajmg.b.20152.
36. Shatunov A, Sambuughin N, Jankovic J, et al. Genomewide scans in
North American families reveal genetic linkage of essential tremor to a region
on chromosome 6p23. Brain 2006;129:2318–2331, doi: http://dx.doi.org/10.
1093/brain/awl120.
37. Kim JH, Cho YH, Kim JK, Park YG, Chang JW. Frequent sequence
variation at the ETM2 locus and its association with sporadic essential tremor in
Korea. Mov Disord 2005;20:1650–1653, doi: http://dx.doi.org/10.1002/mds.
20646.
38. Zahorakova D, Ulmanova O, Kemlink D, et al. No association with the
ETM2 locus in Czech patients with familial essential tremor. Neuro Endocrinol Lett
2010;31:549–552.
39. Inashkina I, Radovica I, Smeltere L, Vitols E, Jankevics E. Case-
control study of patients with essential tremor in Latvia. Eur J Neurol
2008;15:988–990, doi: http://dx.doi.org/10.1111/j.1468-1331.2008.
02225.x.
40. Novelletto A, Gulli R, Ciotti P, et al. Linkage exclusion in Italian families
with hereditary essential tremor. Eur J Neurol 2011;18:e118–120, doi: http://dx.
doi.org/10.1111/j.1468-1331.2011.03458.x.
41. Aridon P, Ragonese P, De Fusco M, Salemi G, Casari G, Savettieri G.
Further evidence of genetic heterogeneity in familial essential tremor.
Parkinsonism Relat Disord 2008;14:15–18, doi: http://dx.doi.org/10.1016/j.
parkreldis.2007.05.002.
42. Illarioshkin SN, Ivanova-Smolenskaya IA, Rahmonov RA, Markova ED,
Stevanin G, Brice A. Clinical and genetic study of familial essential tremor in an
isolate of Northern Tajikistan. Mov Disord 2000;15:1020–1023, doi: http://dx.doi.
org/10.1002/1531-8257(200009)15:5,1020::AID-MDS1044.3.0.CO;2-G.
43. Abbruzzese G, Pigullo S, Di Maria E, et al. Clinical and genetic study of
essential tremor in the Italian population. Neurol Sci 2001;22:39–40, doi: http://
dx.doi.org/10.1007/s100720170036.
44. Kovach MJ, Ruiz J, Kimonis K, et al. Genetic heterogeneity in
autosomal dominant essential tremor. Genet Med 2001;3:197–199, doi: http://
dx.doi.org/10.1097/00125817-200105000-00009.
45. Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain 2007;130:
1456–1464, doi: http://dx.doi.org/10.1093/brain/awm018.
46. Stefansson H, Steinberg S, Petursson H, et al. Variant in the sequence of
the LINGO1 gene confers risk of essential tremor. Nat Genet 2009;41:277–279,
doi: http://dx.doi.org/10.1038/ng.299.
47. Deng H, Gu S, and Jankovic J. LINGO1 variants in essential tremor and
Parkinson’s disease. Acta Neurol Scand 2012;125:1–7, doi: http://dx.doi.org/10.
1111/j.1600-0404.2011.01516.x.
Essential Tremor Genetics Research Challenges Testa CM
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services15
48. Thier S, Lorenz D, Nothnagel M, et al. LINGO1 polymorphisms are
associated with essential tremor in Europeans. Mov Disord 2010;25:709–715,
doi: http://dx.doi.org/10.1002/mds.22887.
49. Vilarino-Guell C, Wider C, Ross OA, et al. LINGO1 and LINGO2
variants are associated with essential tremor and Parkinson disease. Neurogenetics
2010;11:401–408, doi: http://dx.doi.org/10.1007/s10048-010-0241-x.
50. Vilarino-Guell C, Ross OA, Wider C, et al. LINGO1 rs9652490 is
associated with essential tremor and Parkinson disease. Parkinsonism Relat Disord
2010;16:109–111, doi: http://dx.doi.org/10.1016/j.parkreldis.2009.08.006.
51. Clark LN, Park N, Kisselev S, Rios E, Lee JH, Louis ED. Replication of
the LINGO1 gene association with essential tremor in a North American
population. Eur J Hum Genet 2010;18:838–843, doi: http://dx.doi.org/10.1038/
ejhg.2010.27.
52. Radovica I, Inashkina I, Smeltere L, Vitols E, Jankevics E. Screening of
10 SNPs of LINGO1 gene in patients with essential tremor in the Latvian
population. Parkinsonism Relat Disord 2012;18:93–95, doi: http://dx.doi.org/10.
1016/j.parkreldis.2011.06.006.
53. Tan EK, Teo YY, Prakash KM, et al. LINGO1 variant increases risk of
familial essential tremor. Neurology 2009;73:1161–1162, doi: http://dx.doi.org/
10.1212/WNL.0b013e3181bacfc9.
54. Zuo X, Jiang H, Guo JF, et al. Screening for two SNPs of LINGO1 gene
in patients with essential tremor or sporadic Parkinson’s disease in Chinese
population. Neurosci Lett 2010;481:69–72, doi: http://dx.doi.org/10.1016/j.
neulet.2010.06.041.
55. Lorenzo-Betancor O, Garcia-Martin E, Cervantes S, et al. Lack of
association of LINGO1 rs9652490 and rs11856808 SNPs with familial essential
tremor. Eur J Neurol 2011;18:1085–1089, doi: http://dx.doi.org/10.1111/j.
1468-1331.2010.03251.x.
56. Bourassa CV, Riviere JB, Dion PA, et al. LINGO1 variants in the
French-Canadian population. PLoS One 2011;6:e16254, doi: http://dx.doi.org/
10.1371/journal.pone.0016254.
57. Wu YW, Rong TY, Li HH, et al. Analysis of Lingo1 variant in sporadic
and familial essential tremor among Asians. Acta Neurol Scand 2011;124:264–268,
doi: http://dx.doi.org/10.1111/j.1600-0404.2010.01466.x.
58. Wu YW, Prakash KM, Rong TY, et al. Lingo2 variants associated with
essential tremor and Parkinson’s disease. Hum Genet 2011;129:611–615, doi:
http://dx.doi.org/10.1007/s00439-011-0955-3.
59. Liang H, Zheng W, Xu H, et al. No evidence of association between the
LINGO4 gene and essential tremor in Chinese Han patients. Parkinsonism Relat
Disord 2012;18:303–305, doi: http://dx.doi.org/10.1016/j.parkreldis.2011.10.
017.
60. Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP.
A variant in the HS1-BP3 gene is associated with familial essential tremor.
Neurology 2005;64:417–421, doi: http://dx.doi.org/10.1212/01.WNL.
0000153481.30222.38.
61. Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen
L. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord
2006;21:306–309, doi: http://dx.doi.org/10.1002/mds.20692.
62. Deng H, Le WD, Guo Y, Huang MS, Xie WJ, Jankovic J. Extended
study of A265G variant of HS1BP3 in essential tremor and Parkinson disease.
Neurology 2005;65:651–652, doi: http://dx.doi.org/10.1212/01.wnl.
0000173033.32535.23.
63. Shatunov A, Jankovic J, Elble R, et al. A variant in the HS1-BP3 gene is
associated with familial essential tremor. Neurology 2005;65:1995; with author
reply 1995, doi: http://dx.doi.org/10.1212/01.wnl.0000200984.10076.e5.
64. Testa CM, Miyatake L, Wilson M, Bouzyk M, Factor S. Longer REP1
repeat lengths are associated with both essential tremor (ET) and Parkinson
disease (PD). Mov Disord 2008;23:S35, doi: http://dx.doi.org/10.1002/mds.
21727.
65. Jeanneteau F, Funalot B, Jankovic J, et al. A functional variant of the
dopamine D3 receptor is associated with risk and age-at-onset of essential
tremor. Proc Natl Acad Sci USA 2006;103:10753–10758, doi: http://dx.doi.org/
10.1073/pnas.0508189103.
66. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Dopamine
receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor.
Mov Disord 2009;24:1910–1915, doi: http://dx.doi.org/10.1002/mds.22518.
67. Blair MA, Ma S, Phibbs F, et al. Reappraisal of the role of the DRD3
gene in essential tremor. Parkinsonism Relat Disord 2008.
68. Tan EK, Prakash KM, Fook-Chong S, et al. DRD3 variant and risk of
essential tremor. Neurology 2007;68:790–791, doi: http://dx.doi.org/10.1212/
01.wnl.0000256773.87498.2f.
69. Lorenz D, Klebe S, Stevanin G, et al. Dopamine receptor D3 gene
and essential tremor in large series of German, Danish and French patients.
Eur J Hum Genet 2009;17:766–773, doi: http://dx.doi.org/10.1038/ejhg.
2008.243.
70. Vitale C, Gulli R, Ciotti P, et al. DRD3 Ser9Gly variant is not associated
with essential tremor in a series of Italian patients. Eur J Neurol 2008;15:985–
987, doi: http://dx.doi.org/10.1111/j.1468-1331.2008.02164.x.
71. Testa CM. Tremor, essential (syndromes). In: Kompoliti K, Verhagen
L(eds.) The Encyclopedia of Movement Disorders. 2010: Elsevier and Science Direct
(ebook).
72. Vilarino-Guell C, Soto-Ortolaza AI, Rajput A, et al. MAPT H1
haplotype is a risk factor for essential tremor and multiple system atrophy.
Neurology 2011; 76:670–672, doi: http://dx.doi.org/10.1212/WNL.
0b013e31820c30c1.
73. Clark LN, Kisselev S, Park N, et al. Mutations in the Parkinson’s disease
genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA),
are not associated with essential tremor. Parkinsonism Relat Disord 2010;16:132–
135, doi: http://dx.doi.org/10.1016/j.parkreldis.2009.05.008.
74. Vitale C, Ciotti P, Gulli R, et al. Common mutations in the LRRK2
exon 41 are not responsible for essential tremor in Italian patients. Parkinsonism
Relat Disord 2009;15:162–163, doi: http://dx.doi.org/10.1016/j.parkreldis.
2008.04.035.
75. Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, and
Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson’s disease: an etiologic
link with essential tremor? Neurology 2000;54:1195–1198, doi: http://dx.doi.
org/10.1212/WNL.54.5.1195.
76. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a-
synuclein gene identified in families with Parkinson’s disease. Science 1997;276:
2045–2047, doi: http://dx.doi.org/10.1126/science.276.5321.2045.
77. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene
encoding alpha-synuclein in Parkinson’s disease. Nat Genet 1998;18:106–108,
doi: http://dx.doi.org/10.1038/ng0298-106.
Testa CM Essential Tremor Genetics Research Challenges
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services16
78. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation,
E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol
2004;55:164–173, doi: http://dx.doi.org/10.1002/ana.10795.
79. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus
triplication causes Parkinson’s disease. Science 2003;302:841, doi: http://dx.
doi.org/10.1126/science.1090278.
80. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with
parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55:
174–179, doi: http://dx.doi.org/10.1002/ana.10846.
81. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein
locus duplication as a cause of familial Parkinson’s disease. Lancet 2004;364:
1167–1169, doi: http://dx.doi.org/10.1016/S0140-6736(04)17103-1.
82. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between alpha-
synuclein gene duplication and familial Parkinson’s disease. Lancet 2004;364:
1169–1171, doi: http://dx.doi.org/10.1016/S0140-6736(04)17104-3.
83. Mellick GD, Maraganore DM, Silburn PA. Australian data and meta-
analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for
Parkinson’s disease. Neurosci Lett 2005;375:112–116, doi: http://dx.doi.org/10.
1016/j.neulet.2004.10.078.
84. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis
of alpha-synuclein gene promoter variability and Parkinson disease. JAMA
2006;296:661–670, doi: http://dx.doi.org/10.1001/jama.296.6.661.
85. Kruger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to
sporadic Parkinson’s disease by a certain combined alpha-synuclein/apolipo-
protein E genotype. Ann Neurol 1999;45:611–617, doi: http://dx.doi.org/10.
1002/1531-8249(199905)45:5,611::AID-ANA9.3.0.CO;2-X.
86. Farrer M, Maraganore DM, Lockhart P, et al. alpha-Synuclein gene
haplotypes are associated with Parkinson’s disease. Hum Mol Genet 2001;10:
1847–1851, doi: http://dx.doi.org/10.1093/hmg/10.17.1847.
87. Pals P, Lincoln S, Manning J, et al. alpha-Synuclein promoter confers
susceptibility to Parkinson’s disease. Ann Neurol 2004;56:591–595, doi: http://
dx.doi.org/10.1002/ana.20268.
88. Hadjigeorgiou GM, Xiromerisiou G, Gourbali V, et al. Association of
alpha-synuclein Rep1 polymorphism and Parkinson’s disease: influence of Rep1
on age at onset. Mov Disord 2006;21:534–539, doi: http://dx.doi.org/10.1002/
mds.20752.
89. Kay DM, Zabetian CP, Factor SA, et al. Parkinson’s disease and
LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
Mov Disord 2006;21:519–523, doi: http://dx.doi.org/10.1002/mds.20751.
90. Pigullo S, Di Maria E, Marchese R, et al. Essential tremor is not
associated with alpha-synuclein gene haplotypes. Mov Disord 2003;18:823–826,
doi: http://dx.doi.org/10.1002/mds.10421.
91. Ross OA, Conneely KN, Wang T, et al. Genetic variants of alpha-
synuclein are not associated with essential tremor. Mov Disord 2011;26:2552–
2556, doi: http://dx.doi.org/10.1002/mds.23909.
92. Kralic JE, Criswell HE, Osterman JL, et al. Genetic essential tremor in
gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin
Invest 2005;115:774–779.
93. Thier S, Kuhlenbaumer G, Lorenz D, et al. GABA(A) receptor- and
GABA transporter polymorphisms and risk for essential tremor. Eur J Neurol
2011;18:1098–1100, doi: http://dx.doi.org/10.1111/j.1468-1331.2010.03308.
x.
94. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Gamma-
aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for
essential tremor. J Neurol 2011;258:203–211, doi: http://dx.doi.org/10.1007/
s00415-010-5708-z.
95. Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Gamma-
aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms
and risk for essential tremor. Pharmacogenet Genomics 2011;21:436–439, doi:
http://dx.doi.org/10.1097/FPC.0b013e328345bec0.
96. Ledesma MC, Garcia-Martin E, Alonso-Navarro H, et al. The
nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase
is associated to the risk of developing essential tremor. Neuromolecular Med 2008;
10:356–361, doi: http://dx.doi.org/10.1007/s12017-008-8040-3.
97. Keeling BH, Vilarino-Guell C, Soto-Ortolaza AI, et al. Histamine N-
methyltransferase Thr105Ile is not associated with Parkinson’s disease or
essential tremor. Parkinsonism Relat Disord 2010;16:112–114, doi: http://dx.doi.
org/10.1016/j.parkreldis.2009.08.011.
98. Zimprich A. Phenocopies in families with essential tremor and restless
legs syndrome challenge Mendelian laws. Epigenetics might provide answers.
Parkinsonism Relat Disord 2012.
99. Prakash KM, Tan EK. Validity of family history in essential tremor.
Parkinsonism Relat Disord 2008;14:151–153, doi: http://dx.doi.org/10.1016/j.
parkreldis.2007.05.007.
100. Nguyen HV, Ngian V, Cordato D, Shen Q, Chan DK. Quality of life
in a random sample of community dwelling older patients with essential tremor.
Acta Neurol Scand 2007;116:289–292, doi: http://dx.doi.org/10.1111/j.1600-
0404.2007.00863.x.
101. Louis ED, Wendt KJ, Ford B. Senile tremor. What is the prevalence
and severity of tremor in older adults? Gerontology 2000;46:12–16, doi: http://dx.
doi.org/10.1159/000022127.
102. Benito-Leon J, Bermejo-Pareja F, Louis ED. Incidence of essential
tremor in three elderly populations of central Spain. Neurology 2005;64:1721–
1725, doi: http://dx.doi.org/10.1212/01.WNL.0000161852.70374.01.
103. Coriell Institute. http://ccr.coriell.org/Sections/Collections/NINDS/
Population.aspx?PgId5194&coll5ND. 2012.
104. Schrag A, Munchau A, Bhatia KP, Quinn NP, Marsden CD. Essential
tremor: an overdiagnosed condition? J Neurol 2000;247:955–959, doi: http://
dx.doi.org/10.1007/s004150070053.
105. Jain S, Lo SE, Louis ED. Common misdiagnosis of a common
neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol
2006;63:1100–1104, doi: http://dx.doi.org/10.1001/archneur.63.8.1100.
106. Davis CH, Jr., Kunkle EC. Benign essential (heredofamilial) tremor.
AMA Arch Intern Med 1951;87:808–816, doi: http://dx.doi.org/10.1001/
archinte.1951.03810060035004.
107. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and
mortality. Neurology 1967;17:427–442, doi: http://dx.doi.org/10.1212/WNL.
17.5.427.
108. Tse W, Libow LS, Neufeld R, et al. Prevalence of movement disorders
in an elderly nursing home population. Arch Gerontol Geriatr 2008;46:359–366,
doi: http://dx.doi.org/10.1016/j.archger.2007.05.008.
109. Critchley EM. Essential tremor. Lancet 2007;369(9580):2157, doi:
http://dx.doi.org/10.1016/S0140-6736(07)61004-6.
Essential Tremor Genetics Research Challenges Testa CM
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services17
110. Elble RJ, Higgins C, Elble S. Electrophysiologic transition from
physiologic tremor to essential tremor. Mov Disord 2005;20:1038–1042, doi:
http://dx.doi.org/10.1002/mds.20487.
111. Cersosimo MG, Koller WC. Essential tremor. In: Watts RL and Koller
WC (eds.) Movement Disorders: Neurological Principles and Practice, second edition.
2004: McGraw-Hill; pp. 431–458.
112. Testa CM, Rosen AR, Wichmann T, Levey AI, Bouzyk M, Factor SA.
Essential tremor phenotyping and molecular genetics: database cases and a new
large pedigree. Mov Disord 2006;21:S405.
113. Louis ED, Ottman R, Ford B, et al. The Washington Heights-Inwood
Genetic Study of Essential Tremor: methodologic issues in essential-tremor
research. Neuroepidemiology 1997;16:124–133, doi: http://dx.doi.org/10.1159/
000109681.
114. MacMahon B, Pugh TF. Causes and entities of disease. In: Clark DW
and MacMahon B (eds.) Preventive Medicine. 1967, Boston: Little, Brown; p 11–
18. (Available in Evolution of Epidemiologic Ideas: Annotated Readings on
Concepts and Methods, 1987).
115. Elble RJ. Report from a U.S. conference on essential tremor. Mov Disord
2006;21:2052–2061, doi: http://dx.doi.org/10.1002/mds.21157.
116. Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord 2002;
17:638–644, doi: http://dx.doi.org/10.1002/mds.10221.
117. Adler CH, Shill HA, Beach TG. Essential tremor and Parkinson’s
disease: lack of a link. Mov Disord 2011;26:372–377, doi: http://dx.doi.org/10.
1002/mds.23509.
118. Fekete R, Jankovic J. Revisiting the relationship between essential
tremor and Parkinson’s disease. Mov Disord 2011;26:391–398, doi: http://dx.
doi.org/10.1002/mds.23512.
119. Shahed J, Jankovic J. Exploring the relationship between essential
tremor and Parkinson’s disease. Parkinsonism Relat Disord 2007;13:67–76, doi:
http://dx.doi.org/10.1016/j.parkreldis.2006.05.033.
120. Spanaki C, Plaitakis A. Essential tremor in Parkinson’s disease kindreds
from a population of similar genetic background. Mov Disord 2009;24:1662–
1668, doi: http://dx.doi.org/10.1002/mds.22655.
121. Wider C, Ross OA, Wszolek ZK. Genetics of Parkinson disease and
essential tremor. Curr Opin Neurol 2010;23:388–393.
122. Costello S, Bordelon Y, Bronstein J, Ritz B. Familial associations of
Alzheimer disease and essential tremor with Parkinson disease. Eur J Neurol
2010;17:871–878, doi: http://dx.doi.org/10.1111/j.1468-1331.2010.02974.x.
123. Puschmann A, Pfeiffer RF, Stoessl AJ, et al. A family with
Parkinsonism, essential tremor, restless legs syndrome, and depression.
Neurology 2011;76:1623–1630, doi: http://dx.doi.org/10.1212/WNL.
0b013e318219fb42.
124. Zhang J, Carr CW, Rigamonti D, Badr A. Genome-wide linkage scan
maps ETINPH gene to chromosome 19q12-13.31. Hum Hered 2010;69:262–
267, doi: http://dx.doi.org/10.1159/000288711.
125. Cohen O, Pullman S, Jurewicz E, Watner D, Louis ED. Rest tremor in
patients with essential tremor: prevalence, clinical correlates, and electro-
physiologic characteristics. Arch Neurol 2003;60:405–410, doi: http://dx.doi.
org/10.1001/archneur.60.3.405.
126. Rajput AH, Rozdilsky B, Ang L, Rajput A. Significance of parkinsonian
manifestations in essential tremor. Can J Neurol Sci 1993;20:114–117.
127. Koller WC, Rubino FA. Combined resting-postural tremors. Arch Neurol
1985; 42: 683–684, doi: http://dx.doi.org/10.1001/archneur.1985.
04060070073019.
128. Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential
tremor. Neurology 2000;54(11 Suppl 4):S7.
129. Louis ED, Wendt KJ, Pullman SL, Ford B. Is essential tremor
symmetric? Observational data from a community-based study of essential
tremor. Arch Neurol 1998;55:1553–1559, doi: http://dx.doi.org/10.1001/
archneur.55.12.1553.
130. Putzke JD, Whaley NR, Baba Y, Wszolek ZK, Uitti RJ. Essential
tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg
Psychiatry 2006;77:1235–1237.
131. Hubble JP, Busenbark KL, Pahwa R, Lyons K, Koller WC. Clinical
expression of essential tremor: effects of gender and age. Mov Disord 1997;12:
969–972, doi: http://dx.doi.org/10.1002/mds.870120620.
132. Stolze H, Petersen G, Raethjen J, Wenzelburger R, Deuschl G. The
gait disorder of advanced essential tremor. Brain 2001;124:2278–2286, doi:
http://dx.doi.org/10.1093/brain/124.11.2278.
133. Klebe S, Stolze H, Grensing K, Volkmann J, Wenzelburger R,
Deuschl G. Influence of alcohol on gait in patients with essential tremor.
Neurology 2005;65:96–101, doi: http://dx.doi.org/10.1212/01.wnl.
0000167550.97413.1f.
134. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential
tremor. Mov Disord 1994;9:193–196, doi: http://dx.doi.org/10.1002/mds.
870090212.
135. Parisi SL, Heroux ME, Culham EG, Norman KE. Functional mobility
and postural control in essential tremor. Arch Phys Med Rehabil 2006;87:1357–
1364, doi: http://dx.doi.org/10.1016/j.apmr.2006.07.255.
136. Elble RJ, Dubinsky RM, Ala T. Alzheimer’s disease and essential
tremor finally meet. Mov Disord 2007;22:1525–1527, doi: http://dx.doi.org/10.
1002/mds.21595.
137. Schiebler S, Schmidt A, Zittel S, et al. Arm tremor in cervical dystonia–
is it a manifestation of dystonia or essential tremor? Mov Disord 2011;26:1789–
1792, doi: http://dx.doi.org/10.1002/mds.23837.
138. Hedera P, Phibbs FT, Fang JY, Cooper MK, Charles PD, Davis TL.
Clustering of dystonia in some pedigrees with autosomal dominant essential
tremor suggests the existence of a distinct subtype of essential tremor. BMC
Neurol 2010;10:66, doi: http://dx.doi.org/10.1186/1471-2377-10-66.
139. Louis ED, Borden S, Moskowitz CB. Essential tremor centralized brain
repository: diagnostic validity and clinical characteristics of a highly selected
group of essential tremor cases. Mov Disord 2005;20:1361–1365, doi: http://dx.
doi.org/10.1002/mds.20583.
140. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation
and its contribution to complex traits. Nat Rev Genet 2009;10:241–251, doi:
http://dx.doi.org/10.1038/nrg2554.
141. Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. rare allele
hypotheses for complex diseases. Curr Opin Genet Dev 2009;19:212–219, doi:
http://dx.doi.org/10.1016/j.gde.2009.04.010.
142. Li B, Leal SM. Discovery of rare variants via sequencing: implications
for the design of complex trait association studies. PLoS Genet 2009;5:e1000481,
doi: http://dx.doi.org/10.1371/journal.pgen.1000481.
Testa CM Essential Tremor Genetics Research Challenges
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services18
143. Tan EK, Schapira AH. Hunting for genes in essential tremor. Eur J
Neurol 2008;15:889–890, doi: http://dx.doi.org/10.1111/j.1468-1331.2008.
02226.x.
144. Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary
essential tremor. Brain 1994;117:805–824, doi: http://dx.doi.org/10.1093/
brain/117.4.805.
145. Ma S, Davis TL, Blair MA, et al. Familial essential tremor with
apparent autosomal dominant inheritance: should we also consider other
inheritance modes? Mov Disord 2006;21:1368–1374, doi: http://dx.doi.org/10.
1002/mds.20950.
146. Jablonka E, Raz G. Transgenerational epigenetic inheritance: pre-
valence, mechanisms, and implications for the study of heredity and evolution.
Q Rev Biol 2009;84:131–176, doi: http://dx.doi.org/10.1086/598822.
147. Brink RA. A Genetic Change Associated with the R Locus in Maize
Which Is Directed and Potentially Reversible. Genetics 1956;41:872–889.
148. Bennett ST, Wilson AJ, Esposito L, et al. Insulin VNTR allele-specific
effect in type 1 diabetes depends on identity of untransmitted paternal allele.
The IMDIAB Group. Nat Genet 1997;17:350–352, doi: http://dx.doi.org/10.
1038/ng1197-350.
149. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at
base resolution show widespread epigenomic differences. Nature 2009;462:315–
322, doi: http://dx.doi.org/10.1038/nature08514.
150. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and
massively parallel sequencing of 12 human exomes. Nature 2009;461:272–276,
doi: http://dx.doi.org/10.1038/nature08250.
151. Kumar KR, Lohmann K, Klein C. Genetics of Parkinson disease and
other movement disorders. Curr Opin Neurol 2012;25:466–474, doi: http://dx.
doi.org/10.1097/WCO.0b013e3283547627.
152. McCulloch CC, Kay DM, Factor SA, et al. Exploring gene-
environment interactions in Parkinson’s disease. Hum Genet 2008;123:257–
265, doi: http://dx.doi.org/10.1007/s00439-008-0466-z.
153. Tomiyasu A, Nakamura M, Ichiba M, et al. Novel pathogenic mutations
and copy number variations in the VPS13A gene in patients with chorea-
acanthocytosis. Am J Med Genet B Neuropsychiatr Genet 2011;156B:620–631.
154. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic
etiology of Parkinson disease associated with mutations in the SNCA, PARK2,
PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 2010;31:
763–780, doi: http://dx.doi.org/10.1002/humu.21277.
155. Choy KW, Setlur SR, Lee C, Lau TK. The impact of human copy
number variation on a new era of genetic testing. Bjog 2010;117:391–398, doi:
http://dx.doi.org/10.1111/j.1471-0528.2009.02470.x.
156. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington’s
disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg
Psychiatry 2008;79:874–880, doi: http://dx.doi.org/10.1136/jnnp.2007.128728.
157. Factor SA, Steenland NK, Higgins DS, et al. Disease-related and
genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Disord
2011;26:2190–2195, doi: http://dx.doi.org/10.1002/mds.23806.
158. Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Association of
LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control
study. Lancet Neurol 2011;10:898–908, doi: http://dx.doi.org/10.1016/S1474-
4422(11)70175-2.
159. Latourelle JC, Hendricks AE, Pankratz N, et al. Genomewide linkage
study of modifiers of LRRK2-related Parkinson’s disease. Mov Disord 2011;26:
2039–2044, doi: http://dx.doi.org/10.1002/mds.23781.
160. Renegar G, Webster CJ, Stuerzebecher S, et al. Returning genetic
research results to individuals: points-to-consider. Bioethics 2006;20:24–36, doi:
http://dx.doi.org/10.1111/j.1467-8519.2006.00473.x.
Essential Tremor Genetics Research Challenges Testa CM
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services19
